

# **Anxiety and Depression Treatment Market is estimated to be US\$ 13.85 billion by 2030 with a CAGR of 2.7% during the forecast period 2030**

[Anxiety and Depression Treatment Market](#) accounted for US\$ 10.89 billion in 2020 and is estimated to be US\$ 13.85 billion by 2030 and is anticipated to register a CAGR of 2.7%. Anxiety and Depression are two types of mood disorders. Anxiety creates feelings of nervousness, worry or dread. Feeling of sadness, reduced energy and feeling loneliness are symptoms of Depression. Anxiety & Depression lead to chronic fatigue, tiredness & lack of energy. Due to over stress and overthinking the human body cannot handle the emotions and begins to shut down which is manifested by extreme fatigue and tiredness. Covid-19 Pandemic has increased the mental illness among people. Thus, newly drugs, therapies in market are highly recommended.

The report “ **Global Anxiety and Depression Treatment Market By Product (Antidepressant Drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy), By Indication (MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder), Phobia), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030 “**

## **Key Highlights:**

- March 2022, COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. The wakeup call to all countries to step up mental health services and support. Increase in drug development has raised due to pandemic.
- March 2019, FDA approves new nasal spray medication for treatment –resistant depression; available only at a certified doctor’s office or clinic. FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them.

## **Analyst View:**

Due to increase in prevalence of anxiety and depression worldwide. Newly medications is must which are easily available & cost affordable for patients. Increase in research and development to bring up new drug available in market is highly recommended. This can give the boost growth in target market.

**Before purchasing this report, request a sample or make an inquiry by clicking the following link:**

[https://www.prophecymarketinsights.com/market\\_insight/Insight/request-sample/4899](https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4899)

### **Key Market Insights from the report:**

Global Anxiety and Depression Treatment Market accounted for US\$ 10.89 billion in 2020 and is estimated to be US\$ 13.85 billion by 2030 and is anticipated to register a CAGR of 2.7%. The Global Anxiety and Depression Treatment Market is segmented based on Product, Indication, Distribution Channel and Region.

- Based on Product, Global Anxiety and Depression Treatment Market is segmented into Antidepressant drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy.
- Based on Indication, Global Anxiety and Depression Treatment Market is segmented into MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder, Phobia).
- Based on distribution channel, Global Anxiety and Depression Treatment Market is classified into hospital pharmacy, retail pharmacy, and online pharmacy and others.
- By Region, the Global Anxiety and Depression Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

### **Competitive Landscape & their strategies of Anxiety and Depression Treatment:**

The prominent players operating in the Global Anxiety and Depression Treatment Market includes, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., AstraZeneca, Bristol-Myers Squibb, Lundbeck A/S, GlaxoSmithKline plc., Novartis AG, Sanofi, Cipla Ltd., Glenmark Life Sciences Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Intas Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co. Ltd., and Others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

### **Other Topics:**

[https://duediligence.einnews.com/pr\\_news/587695720/immune-health-supplements-market-is-estimated-to-be-us-161-30-billion-by-2030-with-a-cagr-of-11-50-during-the-forecast-period-by-pmi](https://duediligence.einnews.com/pr_news/587695720/immune-health-supplements-market-is-estimated-to-be-us-161-30-billion-by-2030-with-a-cagr-of-11-50-during-the-forecast-period-by-pmi)

[https://eurozone.einnews.com/pr\\_news/587695720/immune-health-supplements-market-is-estimated-to-be-us-161-30-billion-by-2030-with-a-cagr-of-11-50-during-the-forecast-period-by-pmi](https://eurozone.einnews.com/pr_news/587695720/immune-health-supplements-market-is-estimated-to-be-us-161-30-billion-by-2030-with-a-cagr-of-11-50-during-the-forecast-period-by-pmi)